z-logo
open-access-imgOpen Access
<p>CMV Infection: A Clinical Challenge in Biological Therapy? The Case of Asymptomatic Patients with Persistent Positive Immunoglobulin M Anti-CMV Treated with Secukinumab</p>
Author(s) -
Alessio Gambardella,
Gaetano Licata,
Giulia Calabrese,
Alina De Rosa,
Francesca Pagliuca,
Roberto Alfano,
Giuseppe Argenziano
Publication year - 2020
Publication title -
psoriasis
Language(s) - English
Resource type - Journals
ISSN - 2230-326X
DOI - 10.2147/ptt.s284701
Subject(s) - secukinumab , asymptomatic , medicine , cytomegalovirus , immunology , antibody , immune system , psoriasis , herpesviridae , viral disease , virus , psoriatic arthritis
The use of biological therapy is now common practice in the treatment of immune-mediated inflammatory diseases (IMID). Currently, there are no guidelines related to the management of cytomegalovirus (CMV) infections or reactivation during therapy with biological agents. Furthermore, there is a lack of guidance on the management of asymptomatic patients with persistent positive immunoglobulin (Ig)M anti-CMV after an extended period and who have to undergo therapy with biological agents. We report the case of a patient in this situation for whom treatment with biological drugs for psoriasis was indicated. A good clinical response was obtained with secukinumab and maintained during 6 months of follow-up. No infectious disease or reactivation of CMV infection occurred. We suggest some possible guidelines for the management of such cases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here